Immunogen Inc. (IMGN) 4.96 $IMGN
Immunogen Shares Down 26.7% Since SmarTrend's Sell Call (IMGN)
Comtex SmarTrend(R) - Fri Jun 10, 1:27AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on April 29th, 2016 at $6.92. In approximately 1 month, Immunogen has returned 26.73% as of today's recent price of $5.07.
IMGN: 4.96 (-0.11)
ImmunoGen Announces Phase I Cohort Ovarian Cancer Data
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:57AM CDT
ImmunoGen (IMGN) reported efficacy and safety phase I cohort data evaluating mirvetuximab soravtansine as a single-agent therapy for ovarian cancer.
ANIP: 52.05 (-1.64), IMGN: 4.96 (-0.11), RTRX: 17.40 (-0.30), BMY: 72.65 (-0.08)
ImmunoGen Reports Efficacy and Safety Data from a 46-Patient Cohort of Mirvetuximab Soravtansine in FRa-Positive Ovarian Cancer
BusinessWire - Wed May 18, 4:01PM CDT
--Company preparing to meet with FDA in early 3Q2016; targeting initiation of Phase 3 study in 4Q2016.
IMGN: 4.96 (-0.11)
Shares of IMGN Down 19.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed May 18, 1:30PM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on April 29th, 2016 at $6.92. In approximately 3 weeks, Immunogen has returned 19.08% as of today's recent price of $5.60.
IMGN: 4.96 (-0.11)
ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences
BusinessWire - Wed May 11, 7:30AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
IMGN: 4.96 (-0.11)
ImmunoGen (IMGN) Posts Wider-than-Expected Q3 Loss
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:51AM CDT
ImmunoGen (IMGN) reports a loss of 37 cents per share wider than the Zacks Consensus Estimate of a loss of 30 cents.
GILD: 84.45 (-1.32), IMGN: 4.96 (-0.11), AEGR: 1.37 (-0.13)
Why ImmunoGen, Inc. Was Down Today (Hint: It Wasn't Earnings)
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 29, 2:33PM CDT
What: ImmunoGen reported its fiscal third-quarter earnings on Friday, and fell as much as 22%, but it wasn't the biotech's revenue or loss that has investors hitting the sell button. So what: For the record, ImmunoGen reported revenue of $19.7...
IMGN: 4.96 (-0.11)
Drug Stocks' Earnings Previews: KERX, BXLT, BMRN, AGEN, IMGN
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 11:10AM CDT
With the first-quarter earnings season in full swing, investors are possibly seeing a ray of hope, as results reported so far have not been as dismal as expected.
AGEN: 4.00 (-0.19), BIIB: 246.13 (-4.33), JNJ: 117.01 (+0.01), BMRN: 81.10 (-1.84), SHPG: 177.10 (-6.85), IMGN: 4.96 (-0.11), BXLT: 46.02 (-0.18), KERX: 5.93 (-0.12), NVS: 78.94 (-1.57)
What's in the Cards for ImmunoGen (IMGN) in Q3 Earnings?
Ananya Ghosh - Zacks Investment Research - Tue Apr 26, 3:13PM CDT
ImmunoGen (IMGN) will report third-quarter fiscal 2016 results on Apr 29 before the market opens.
INVA: 11.35 (-0.21), IMGN: 4.96 (-0.11), SNY: 39.41 (-1.45)
ImmunoGen Appoints Mark J. Enyedy as President and Chief Executive Officer
BusinessWire - Tue Apr 26, 7:00AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that Mark J. Enyedy has been appointed President and CEO and elected to the Board of Directors, effective May 16, 2016. Mr. Enyedy succeeds Daniel Junius, who as previously announced is retiring from these positions and will continue to serve on ImmunoGen's Board.
IMGN: 4.96 (-0.11)
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2016 Financial Results
BusinessWire - Mon Apr 11, 10:30AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 29, 2016, to discuss ImmunoGen's financial results for the three-month period ended March 31, 2016. Management also will provide an update on mirvetuximab soravtansine and other ImmunoGen product programs.
IMGN: 4.96 (-0.11)
Daniel Junius to Retire as President and CEO of ImmunoGen, Inc.
BusinessWire - Tue Apr 05, 7:00AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius, age 63, has decided to retire from his positions of President and CEO of the Company. This will become effective when his successor joins ImmunoGen. Mr. Junius has been the Company's CEO since January 2009. Following his retirement, Mr. Junius will continue to serve on ImmunoGen's Board of Directors.
IMGN: 4.96 (-0.11)
ImmunoGen, Inc. Announces Presentations at Upcoming AACR Annual Meeting
BusinessWire - Tue Mar 29, 3:30PM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentations related to the Company's technology portfolio to be made at the American Association for Cancer Research (AACR) annual meeting being held April 16-20, 2016 in New Orleans, LA.
IMGN: 4.96 (-0.11)
GlycoMimetics Appoints ImmunoGen CEO Daniel Junius to Board of Directors
BusinessWire - Mon Mar 21, 8:30AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Daniel Junius to its Board of Directors. Mr. Junius is President and Chief Executive Officer and a member of the board of directors of ImmunoGen, Inc., an industry leader in the field of antibody drug conjugates (ADCs). He also serves on the Board of Directors of IDEXX Laboratories, a leading provider of diagnostic and information technology-based products and services for pet healthcare innovation.
IMGN: 4.96 (-0.11), GLYC: 8.50 (+0.13)
Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 80.41 (-1.20), IMGN: 4.96 (-0.11), ARQL: 1.78 (unch), LLY: 73.95 (-0.48), GSK: 40.93 (-1.13), ONTY: 1.21 (+0.02), MDVN: 60.01 (-0.09), MRK: 56.81 (-0.37), AZN: 27.97 (-0.99), AVEO: 1.03 (-0.03), GALE: 2.08 (+0.10), PBYI: 33.41 (-0.43), NVS: 78.94 (-1.57), KPTI: 8.53 (-0.60), XLRN: 35.44 (+0.94), EXEL: 7.38 (+0.01)
ImmunoGen/Merck Collaborate for Ovarian Cancer Study
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 4:00PM CST
ImmunoGen (IMGN) & Merck tie up to evaluate mirvetuximab soravtansine in combination with Keytruda for ovarian cancer.
MRK: 56.81 (-0.37), IMGN: 4.96 (-0.11), LGND: 113.74 (-1.34), CELG: 102.91 (-3.22)
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfgg5w/relapsed_chronic) has announced the addition of the "Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsed Chronic Lymphocytic Leukemia (CLL) Overview - Therapeutics Development - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cyclacel Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hutchison MediPharma Limited - ImmunoGen, Inc. - Immunomedics, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Innate Pharma SA - Juno Therapeutics Inc. - Karyopharm Therapeutics, Inc. - Les Laboratoires Servier SAS - LFB S.A. - Lymphocyte Activation Technologies, S.A. - MedImmune, LLC - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Ono Pharmaceutical Co., Ltd. - Portola Pharmaceuticals, Inc. - Sanofi - TG Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rf...ed_chronic
CYCC: 5.95 (-0.14), ABBV: 61.00 (+0.25), INFI: 4.81 (-0.23), JUNO: 42.98 (-2.55), IMMU: 3.05 (-0.08), PTLA: 26.38 (-0.46), EBS: 42.30 (-1.19), INCY: 80.41 (-1.20), IMGN: 4.96 (-0.11), TGTX: 7.16 (-0.23), BMY: 72.65 (-0.08), GILD: 84.45 (-1.32), AZN: 27.97 (-0.99), CELGZ: 1.46 (-0.04), KPTI: 8.53 (-0.60), NVS: 78.94 (-1.57)
Immunogen Shares Down 26.7% Since SmarTrend's Sell Call (IMGN)
Comtex SmarTrend(R) - Fri Jun 10, 1:27AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on April 29th, 2016 at $6.92. In approximately 1 month, Immunogen has returned 26.73% as of today's recent price of $5.07.
IMGN: 4.96 (-0.11)
ImmunoGen Announces Phase I Cohort Ovarian Cancer Data
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:57AM CDT
ImmunoGen (IMGN) reported efficacy and safety phase I cohort data evaluating mirvetuximab soravtansine as a single-agent therapy for ovarian cancer.
ANIP: 52.05 (-1.64), IMGN: 4.96 (-0.11), RTRX: 17.40 (-0.30), BMY: 72.65 (-0.08)
ImmunoGen Reports Efficacy and Safety Data from a 46-Patient Cohort of Mirvetuximab Soravtansine in FRa-Positive Ovarian Cancer
BusinessWire - Wed May 18, 4:01PM CDT
--Company preparing to meet with FDA in early 3Q2016; targeting initiation of Phase 3 study in 4Q2016.
IMGN: 4.96 (-0.11)
Shares of IMGN Down 19.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed May 18, 1:30PM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on April 29th, 2016 at $6.92. In approximately 3 weeks, Immunogen has returned 19.08% as of today's recent price of $5.60.
IMGN: 4.96 (-0.11)
ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences
BusinessWire - Wed May 11, 7:30AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
IMGN: 4.96 (-0.11)
ImmunoGen (IMGN) Posts Wider-than-Expected Q3 Loss
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:51AM CDT
ImmunoGen (IMGN) reports a loss of 37 cents per share wider than the Zacks Consensus Estimate of a loss of 30 cents.
GILD: 84.45 (-1.32), IMGN: 4.96 (-0.11), AEGR: 1.37 (-0.13)
Why ImmunoGen, Inc. Was Down Today (Hint: It Wasn't Earnings)
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 29, 2:33PM CDT
What: ImmunoGen reported its fiscal third-quarter earnings on Friday, and fell as much as 22%, but it wasn't the biotech's revenue or loss that has investors hitting the sell button. So what: For the record, ImmunoGen reported revenue of $19.7...
IMGN: 4.96 (-0.11)
Drug Stocks' Earnings Previews: KERX, BXLT, BMRN, AGEN, IMGN
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 11:10AM CDT
With the first-quarter earnings season in full swing, investors are possibly seeing a ray of hope, as results reported so far have not been as dismal as expected.
AGEN: 4.00 (-0.19), BIIB: 246.13 (-4.33), JNJ: 117.01 (+0.01), BMRN: 81.10 (-1.84), SHPG: 177.10 (-6.85), IMGN: 4.96 (-0.11), BXLT: 46.02 (-0.18), KERX: 5.93 (-0.12), NVS: 78.94 (-1.57)
What's in the Cards for ImmunoGen (IMGN) in Q3 Earnings?
Ananya Ghosh - Zacks Investment Research - Tue Apr 26, 3:13PM CDT
ImmunoGen (IMGN) will report third-quarter fiscal 2016 results on Apr 29 before the market opens.
INVA: 11.35 (-0.21), IMGN: 4.96 (-0.11), SNY: 39.41 (-1.45)
ImmunoGen Appoints Mark J. Enyedy as President and Chief Executive Officer
BusinessWire - Tue Apr 26, 7:00AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that Mark J. Enyedy has been appointed President and CEO and elected to the Board of Directors, effective May 16, 2016. Mr. Enyedy succeeds Daniel Junius, who as previously announced is retiring from these positions and will continue to serve on ImmunoGen's Board.
IMGN: 4.96 (-0.11)
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2016 Financial Results
BusinessWire - Mon Apr 11, 10:30AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 29, 2016, to discuss ImmunoGen's financial results for the three-month period ended March 31, 2016. Management also will provide an update on mirvetuximab soravtansine and other ImmunoGen product programs.
IMGN: 4.96 (-0.11)
Daniel Junius to Retire as President and CEO of ImmunoGen, Inc.
BusinessWire - Tue Apr 05, 7:00AM CDT
ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius, age 63, has decided to retire from his positions of President and CEO of the Company. This will become effective when his successor joins ImmunoGen. Mr. Junius has been the Company's CEO since January 2009. Following his retirement, Mr. Junius will continue to serve on ImmunoGen's Board of Directors.
IMGN: 4.96 (-0.11)
ImmunoGen, Inc. Announces Presentations at Upcoming AACR Annual Meeting
BusinessWire - Tue Mar 29, 3:30PM CDT
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentations related to the Company's technology portfolio to be made at the American Association for Cancer Research (AACR) annual meeting being held April 16-20, 2016 in New Orleans, LA.
IMGN: 4.96 (-0.11)
GlycoMimetics Appoints ImmunoGen CEO Daniel Junius to Board of Directors
BusinessWire - Mon Mar 21, 8:30AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Daniel Junius to its Board of Directors. Mr. Junius is President and Chief Executive Officer and a member of the board of directors of ImmunoGen, Inc., an industry leader in the field of antibody drug conjugates (ADCs). He also serves on the Board of Directors of IDEXX Laboratories, a leading provider of diagnostic and information technology-based products and services for pet healthcare innovation.
IMGN: 4.96 (-0.11), GLYC: 8.50 (+0.13)
Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 80.41 (-1.20), IMGN: 4.96 (-0.11), ARQL: 1.78 (unch), LLY: 73.95 (-0.48), GSK: 40.93 (-1.13), ONTY: 1.21 (+0.02), MDVN: 60.01 (-0.09), MRK: 56.81 (-0.37), AZN: 27.97 (-0.99), AVEO: 1.03 (-0.03), GALE: 2.08 (+0.10), PBYI: 33.41 (-0.43), NVS: 78.94 (-1.57), KPTI: 8.53 (-0.60), XLRN: 35.44 (+0.94), EXEL: 7.38 (+0.01)
ImmunoGen/Merck Collaborate for Ovarian Cancer Study
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 4:00PM CST
ImmunoGen (IMGN) & Merck tie up to evaluate mirvetuximab soravtansine in combination with Keytruda for ovarian cancer.
MRK: 56.81 (-0.37), IMGN: 4.96 (-0.11), LGND: 113.74 (-1.34), CELG: 102.91 (-3.22)
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfgg5w/relapsed_chronic) has announced the addition of the "Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsed Chronic Lymphocytic Leukemia (CLL) Overview - Therapeutics Development - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cyclacel Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hutchison MediPharma Limited - ImmunoGen, Inc. - Immunomedics, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Innate Pharma SA - Juno Therapeutics Inc. - Karyopharm Therapeutics, Inc. - Les Laboratoires Servier SAS - LFB S.A. - Lymphocyte Activation Technologies, S.A. - MedImmune, LLC - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Ono Pharmaceutical Co., Ltd. - Portola Pharmaceuticals, Inc. - Sanofi - TG Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rf...ed_chronic
CYCC: 5.95 (-0.14), ABBV: 61.00 (+0.25), INFI: 4.81 (-0.23), JUNO: 42.98 (-2.55), IMMU: 3.05 (-0.08), PTLA: 26.38 (-0.46), EBS: 42.30 (-1.19), INCY: 80.41 (-1.20), IMGN: 4.96 (-0.11), TGTX: 7.16 (-0.23), BMY: 72.65 (-0.08), GILD: 84.45 (-1.32), AZN: 27.97 (-0.99), CELGZ: 1.46 (-0.04), KPTI: 8.53 (-0.60), NVS: 78.94 (-1.57)
